Skip to main content

Table 2 Patient characteristics and characterization of cell products

From: Safety and tolerability of intradiscal implantation of combined autologous adipose-derived mesenchymal stem cells and hyaluronic acid in patients with chronic discogenic low back pain: 1-year follow-up of a phase I study

  Patient number
  1 2 3 4 5 6 7 8 9 10
Sex (M/F) F F F M M M F M M M
Age (years) 37 42 49 42 44 41 30 32 64 54
BMI (kg/m2) 27.9 22.6 26.5 22.2 20.3 38 20.2 26.7 23.1 23.5
Hypertension (yes/no) N N Y N N Y N N N N
Diabetes mellitus (yes/no) N N N N N N N N N N
Smoking history (yes/no) N N N N N Y N N Y N
Duration of LBP (months) 96 12 14 29 7 37 96 72 36 84
Implanted disc level L4/5 L4/5 L4/5 L4/5 L4/5 L4/5, L5/S1 L4/5 L4/5 L4/5 L4/5
Preoperative VAS 8 7 6 7 4 7 6 6 6 7
Preoperative ODI 40 34 30 50 32 72 54 32 32 60
Preoperative Pfirrmann’s grade IV IV IV IV IV IV IV IV IV IV
Cell number (× 107/vial) 4.7 5.3 5.4 5.3 5.4 5.0 5.3 5.0 5.2 4.7
Cell viability (%) 93.62 91.55 97.57 88.30 97.09 89.44 87.13 94.38 94.55 89.93
Cell surface marker CD44 (%) 94.50 84.80 98.00 99.90 99.90 100 99.8 99.9 98.3 99.2
CD73 (%) 98.40 98.60 99.90 100.00 99.60 100 100 100 99.9 99.9
CD45 (%) 1.00 0.81 0.20 0.48 0.51 0.75 0.19 0.49 0.7 0.67
CD29 (%) 90.80 97.50 99.80 99.90 99.90 100.00 100.00 100.00 100.00 99.90
TGF-β receptor III 98.20 99.10 99.60 100.00 99.70 99.10 99.90 100.00 99.40 99.80
  1. M male, F female, BMI body mass index, LBP low back pain, VAS visual analogue scale, ODI Oswestry Disability Index, TGF-β transforming growth factor beta